Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa

NCT00432913 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2008-10-17

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of two doses purified EPA (an omega-3 fatty acid), on apoptosis (natural cell death) and cell proliferation (formation of new cells) in the lining of the colon for patients with a history of colonic polyps.

Conditions

  • Adenomatous Polyps

Interventions

DRUG

Eicosapentaenoic Acid (EPA)

Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)

PROCEDURE

Endoscopy

At baseline, month 3 and month 6.

PROCEDURE

Biopsies taken

9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.

PROCEDURE

Clinical chemistry

Full blood count at baseline, month 3 and month 6.

PROCEDURE

Haematology

Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.

PROCEDURE

Physical examination

Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.

PROCEDURE

Vital signs

Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.

PROCEDURE

Urine pregnancy test

For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.

PROCEDURE

Completion of patient diary card

Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.

Sponsors & Collaborators

  • S.L.A. Pharma AG

    lead INDUSTRY

Principal Investigators

  • Nicholas J West, MB BS FRCS · St. George's Hospital Medical School, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00432913 on ClinicalTrials.gov